GeNeuro: financial information and business update for the fourth quarter 2019

Geneva, Switzerland, January 30, 2020 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced its cash position at December 31, 2019, issued a business update and provided an outlook on its 2020 activities.